| Francesco Galimi |
Francesco Galimi is currently the Chief Medical Officer & Senior Vice President at Adicet Therapeutics, Inc. and Adicet Bio, Inc. He previously worked as the General Manager-Global Program at Amgen, Inc. from 2015 to 2019 and as the Head-Clinical Development at Onyx Pharmaceuticals, Inc. from 2014 to 2015. He also served as the Chief Medical Officer & Senior Vice President at resTORbio, Inc. Dr. Galimi earned a doctorate degree from the University of Turin. |
| Donald Healey |
Donald Healey is currently the Chief Technology Officer at Adicet Bio, Inc. He was previously the Senior Vice President-Operations at KBI Biopharma, Inc. from 2017 to 2020 and the Chief Scientific Officer at Opexa Therapeutics, Inc. from 2013 to 2017. He also worked as the Director-Immunology at Argos Therapeutics, Inc. and as a Council Member at the British Society for Immunology. He holds a doctorate degree from the University of London and an undergraduate degree from the University of Bristol. |
| Nancy L. Boman |
Nancy L. Boman is currently the Chief Regulatory Officer & Senior Vice President at Adicet Bio, Inc. She previously worked as a Principal at Amgen, Inc., Genentech, Inc., and QLT, Inc. She also served as the SVP-Clinical Development & Regulatory Affairs at CTI BioPharma Corp. from 2013 to 2016. Additionally, she held positions as VP-Clinical Development & Regulatory Affairs at Acucela, Inc. and Senior Vice President-Regulatory Affairs at Lundbeck Seattle BioPharmaceuticals, Inc. She was also the Chief Regulatory Officer at Novartis Gene Therapies, Inc. and Encoded Therapeutics, Inc. Dr. Boman received her undergraduate and doctorate degrees from the University of British Columbia. |
| Brian Nicholas Harvey |
Brian Nicholas Harvey's current job(s) include Director at Passport Systems, Inc. and Chief Financial & Accounting Officer at Adicet Bio, Inc. His former job(s) include CFO, Secretary, Treasurer & Director at MPM Acquisition Corp., Managing Director at Shiprock Capital LLC, Chief Financial Officer at Transcend Therapeutics, Inc., CFO, Secretary, Treasurer & Senior Vice President at Radius Health, Inc., Chief Financial Officer, Treasurer & Executive VP at Centrexion Therapeutics Corp., Chief Financial Officer at Transfusion Technologies Corp., and Chief Financial Officer at Lifetecnet. Mr. Harvey's education history includes an undergraduate and graduate degree from The Australian National University and an MBA from Harvard Business School. |
| Blake Aftab |
Blake Aftab is currently the Chief Scientific Officer & Senior Vice President at Adicet Bio, Inc. He previously worked as the Vice President & Head-Preclinical Science at Atara Biotherapeutics, Inc. Dr. Aftab completed his undergraduate degree at the University of California, Santa Barbara and holds a doctorate from The Johns Hopkins University School of Medicine. |
| Carl Lee Gordon |
Carl Lee Gordon founded OrbiMed Advisors LLC. He occupies the position of Chairman for Compass Therapeutics, Inc., Chairman at Adicet Bio, Inc., Managing Partner at OrbiMed Advisors LLC, Managing Partner at OrbiMed Advisors Private Equity (a subsidiary of OrbiMed Advisors LLC) and Principal at Aragon Pharmaceuticals, Inc. Dr. Gordon is also on the board of 23 other companies. Dr. Gordon was a Senior Biotechnology Analyst at OrbiMed’s predecessor firm Mehta and Isaly.
Dr. Gordon was a Fellow at The Rockefeller University from 1993 to 1995. Dr. Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and a Bachelor of Arts Degree from Harvard College. |
| Amy Locke |
Amy Locke is currently the Chief Human Resources Officer at Adicet Bio, Inc. She started this position in 2022. Prior to her current role, she obtained an undergraduate degree from the University of North Texas. |
| Chen Schor |
Chen Schor was the founder of resTORbio, Inc. (founded in 2016) and held the title of President, CEO, CFO, Secretary & Director. He is currently the Chief Executive Officer at Adicet Therapeutics, Inc., President, Chief Executive Officer & Director at Adicet Bio, Inc., Chairman at Carbon Biosciences, Inc., Director at Otic Pharma Ltd., and Director at Alliance for Cancer Gene Therapy, Inc. He is also an Independent Director at Karyopharm Therapeutics, Inc. (since 2020). Previously, he held positions such as President, Chief Executive Officer & Director at Synta Pharmaceuticals Corp. (2014-2016), President, Chief Executive Officer & Director at Novalere, Inc., Director at Brainstorm Cell Therapeutics, Inc. (2011-2020), Director at Gelesis, Inc., Director at Cerapedics, Inc., Director at Quiet Therapeutics Ltd., Vice President-Business Development at Teva Pharmaceutical Industries Ltd. (2009-2011), Chief Business Officer at EPIX Pharmaceuticals, Inc. (2003-2009), Chief Business Officer at Predix Pharmaceuticals, Inc. (2003-2009), VP-Business Development, Global Branded Products at Teva Pharmaceuticals USA, Inc. (2009-2011), Partner at XT Hi-. Tech Investments (1992) Ltd. (1998-2003), Principal at Arthur Anderson & Co., Chief Business Officer at Sesen Bio, Inc. (2011-2012), and Partner at Yozma Venture Capital Ltd. He has an undergraduate degree and an MBA from Tel-Aviv University and an undergraduate degree from the University of Haifa. |
| Katie Peng |
Katie Peng is an Independent Director at Scholar Rock Holding Corp., a Director at California Life Sciences Association, and an Independent Director at Adicet Bio, Inc. She was previously a Senior Vice President & Head-OMNI Business Unit at Genentech, Inc. She received an undergraduate degree from the University of California, Berkeley and an MBA from Kelley School of Business. Additionally, she is currently the Chief Commercial Officer at Denali Therapeutics, Inc. |
| Jeffrey Allan Chodakewitz |
Jeffrey Allan Chodakewitz is currently an Independent Director at Schrödinger, Inc., a Director at Freeline Therapeutics Ltd., an Independent Director at Praxis Precision Medicines, Inc., and an Independent Director at Adicet Bio, Inc. He is also a Member of the Infectious Diseases Society of America and The American Society for Clinical Pharmacology & Therapeutics. Previously, he served as an Independent Director at Tetraphase Pharmaceuticals, Inc., Director-HIV Outpatient Clinic at Veterans Administration Medical Center, Director at Adicet Therapeutics, Inc., Independent Director at resTORbio, Inc., and Independent Non-Executive Director at Freeline Therapeutics Holdings Plc. He was also the Head-Infectious Diseases & Vaccines Global at Merck & Co., Inc. and EVP-Clinical Medicine & External Innovations at Vertex Pharmaceuticals, Inc. Chodakewitz received his undergraduate degree from Yale University and his doctorate from Yale School of Medicine. |
| Steve Dubin |
Steve Dubin is currently the Chairman of the Maryland Economic Development Commission, Vice Chairman of The Brain Center LLC, Director of The UCAN Co., Director of Maryland, Director of Alcresta Therapeutics, Inc., Director of Oceans Omega LLC, Director of Triton Algae Innovations Ltd., Director of Alcresta, Inc. (New Jersey), Director of Phytolon Ltd., Independent Director of Adicet Bio, Inc., Member of the Maryland State Bar Association, and Senior Advisor of AquAgro Ventures Ltd. Previously, Mr. Dubin served as the Chief Executive Officer & Director of Martek Biosciences Corp. from 2006 to 2011. He was also the Chairman of Enzymotec Ltd. from 2014 to 2018. Additionally, he held positions as a Director in Mycell Technologies LLC, Scerene Healthcare, Inc., resTORbio, Inc., Martek Biosciences Corp., Suburban Capital Corp., Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC, Chesapeake Emerging Opportunities Management LLC, Angel-Investing Club, SDA Ventures LLC, and President-Nutritional Lipids Division of DSM Inc.Mr. Dubin obtained his undergraduate degree from the University of Maryland and his graduate degree from George Washington University Law School. |
| Michael G. Kauffman |
Michael G. Kauffman was the founder of Karyopharm Therapeutics, Inc. (founded in 2008) and held the title of Director. He is also the founder of Millennium Predictive Medicine, Inc. Dr. Kauffman's current job positions include President, Chief Executive Officer & Director at Nereid Therapeutics, Inc. (since 2023), Chairman at Verastem, Inc. (since 2012), Non-Executive Chairman at BiVictriX Therapeutics Plc (since 2022), Independent Director at Kezar Life Sciences, Inc. (since 2016), Independent Director at Adicet Bio, Inc. (since 2021), Director at Mirror Biologics Inc, and Advisor at Prime Movers Lab LLC. His former job positions include Chief Executive Officer at EPIX Pharmaceuticals, Inc. (2006-2008), Chief Executive Officer at Predix Pharmaceuticals, Inc. (2002-2006), Medical Director at Biogen, Inc. (1995-1997), Director at CombinatoRx, Inc. (2006-2009), Director at Metamark Genetics, Inc. (2012), Independent Director at Infinity Pharmaceuticals, Inc. (2017-2020), Director at Zalicus, Inc. (2006-2014), Director at Excision BioTherapeutics, Inc., Advisor at Bessemer Venture Partners LP (2009-2010), and Executive Vice President-Distribution Operations at The Jones Group, Inc. He also held the position of Vice President-Clinical at Millennium Pharmaceuticals, Inc. (2000-2002), Chief Medical Officer at Onyx Pharmaceuticals, Inc. (2009-2010), and Chief Medical Officer at Proteolix, Inc. (2008-2009). Dr. Kauffman's education includes an undergraduate degree from Amherst College and a doctorate degree from The Johns Hopkins University School of Medicine (conferred in 1992). Dr. Kauffman is also the founder of Millennium Predictive Medicine, Inc... |
| Aya Jakobovits |
Aya Jakobovits is the founder of Adicet Bio, Inc. (founded in 2014) and holds the title of Independent Director. Dr. Jakobovits is also the founder of Adicet Therapeutics, Inc... Dr. Jakobovits's current jobs include Director positions at Yeda Research & Development Co. Ltd., UCLA Technology Development Group, Dyve Biosciences, Inc., and Dorian Therapeutics, Inc. Dr. Jakobovits's former jobs include President, Chief Executive Officer & Director at Kite Pharma, Inc. (2010-2013), Director-Molecular Immunology at Cell Genesys, Inc. (1986-1996), Director-Discovery Research & Principal Scientist at Abgenix, Inc. (1996-1999), Director at Alliance for Cancer Gene Therapy, Inc. (2015-2019), Director at cCAM Biotherapeutics Ltd. (2013-2015), Director at resTORbio, Inc., Chief Scientific Officer & Senior Vice President at Agensys, Inc. (2013), and Venture Partner at OrbiMed Advisors Private Equity (2013-2015). Dr. Jakobovits's education includes an undergraduate degree from The Hebrew University of Jerusalem and graduate and doctorate degrees from the Weizmann Institute of Science. |
| Andrew Sinclair |
Andrew Sinclair is currently an Independent Director at Soleno Therapeutics, Inc. and a Managing Director at Abingworth LLP. He is also an Independent Director at Adicet Bio, Inc., a Director at Locki Therapeutics Ltd., and a Director at Entact Bio, Inc. In addition, Dr. Sinclair is a Portfolio Manager & Partner at Abingworth Management Ltd. He is a Member of the Institute of Chartered Accountants in England & Wales. Previously, he served as an Independent Director at Sierra Oncology, Inc. from 2019 to 2022. He was also a Director at HSBC Global Markets Select Funds Plc, a Director at Abingworth Bioventures VI LP from 2016 to 2020, and an Independent Non-Executive Director at Verona Pharma Plc. Dr. Sinclair worked as a Research Analyst at Credit Suisse Securities (Europe) Ltd. and as a Research Analyst at HSBC Bank Plc (Broker) from 2007 to 2008. He obtained his undergraduate degree from King's College London. |
